Figure5 .

LIMT could regulate sorafenib resistance through regulating miR-665 and EMT(A–C) HCC cells were treated with the LIMT siRNA alone or combined with miR-665 inhibitor, following treatment with sorafenib, and cell viability was examined by CCK-8 assay. (D) The rate of invasive HCC cells treated with LIMT siRNA alone or combined with miR-665 inhibitor following treatment with sorafenib were determined by Transwell invasion analysis. **P<0.01 and ***P<0.001. (E) The levels of FN-1, E-cadherin, Vimentin and Twist 1 proteins were determined by western blot analysis.